Ideaya Biosciences Initiated Part 2 Monotherapy Expansion In Its Phase 1/2 Trial Of IDE892 In Mtap-Deleted Solid Tumors, With A Focus On Non-small Cell Lung Cancer And Pancreatic Ductal Adenocarcinoma
IDEAYA Biosciences Inc IDYA
$35.50
▼ -2.47%
($-0.90)
📅 Earnings This Week
Open
$36.37
Prev Close
$36.40
Day Range
$35.29 – $36.63
52W Range
$22.09 – $40.58
Market Cap
$3.38B
Beta
-0.10
EPS (TTM)
$-1.60
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-05-23 |
| Shares Out. | 95,080,000 |
| Website | ideayabio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 145 |
| Revenue | $6.6M |
| Gross Profit | $6.6M |
| Net Income | -$98.5M |
| Free Cash Flow | -$87.9M |
| Total Assets | $1.03B |
| Total Liabilities | $93.1M |
| Equity | $937.3M |
About IDEAYA Biosciences Inc
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
IDEAYA Biosciences Inc is a publicly traded company under the ticker symbol IDYA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
23 analysts (2026-07-01)